Actual Medicinal Product (AMP) Co-amoxiclav 500mg/125mg tablets (APC Pharmaceuticals & Chemicals (Europe) Ltd)
Stability Information
(Some stability information inherited from generic)
- Stability
-
There are concerns about stability and/or there is a lack of stability data available. These medicines can theoretically be used in MCAs, although use is likely to be off-label. Mitigation measures may need to be considered. Keep medicines in MCAs for the shortest time necessary. Generally, up to 5 weeks maximum unless otherwise specified, or consider up to 8 weeks if the MCA is airtight (sealed). Consider the risk to the individual from potency loss or dose variability, particularly with unsealed devices. Monitor for any changes in therapeutic effect or increased adverse effects after MCA initiation.
- Notes
-
Clavulanate powder is hygroscopic. Avoid exposure to excessive humidity. Store in tight containers. Maximum of 7 days in MCA.
- Provenance
-
This compatibility recommendation is derived from Augmentin 625mg tablets (GlaxoSmithKline UK Ltd) and Co-amoxiclav 500mg/125mg tablets (Sandoz Ltd).
- Generic
- Co-amoxiclav
- Formulation
- Co-amoxiclav 500mg/125mg tablets
-
Co-amoxiclav
-
Co-amoxiclav 500mg/125mg tablets
-
Co-amoxiclav 500mg/125mg tablets (APC Pharmaceuticals & Chemicals (Europe) Ltd)
-
-
Co-amoxiclav 875mg/125mg tablets